Avalo Therapeutics, Inc. AVTX
Avalo Therapeutics, Inc. (Nasdaq: AVTX) is an immunology/inflammation drug developer. Its lead program, abdakibart (AVTX-009), is in Phase 2 for hidradenitis suppurativa.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| abdakibart (AVTX-009) | hidradenitis suppurativa | antibody | Phase 2 |
| AVTX-010 | IL-1beta driven indications | antibody | Pre-clinical |
Recent results and decisions
- May 5, 2026met Phase 2 LOTUS met primary endpoint HiSCR75 at Week 16: 42.2% (150 mg Q2W, p=0.018) and 42.9% (300 mg Q4W, p=0.015) vs 25.6% placebo; combined 42.5% (p=0.004); HiSCR50 and IHS4 also significant.
The LOTUS trial successfully met its primary endpoint at both doses studied.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.